Across TCGA pan-cancer cohorts, CASP16P Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated CASP16P data layer compared with 24 for mass-spec protein.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher CASP16P Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CASP16P expression acts as an unfavorable survival marker.

CHOL are the cancer types where CASP16P Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	OS	Median	All	0.155	0.725	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: CASP16P tumor-vs-normal RNA expression · all CASP16P data types